Monographie - Mitomycin

Senaste uppdateringen :
19/11/2024

Mitomycin

Molekylstruktur

Varunamn

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Ametycine	Frankrike
Crisofimina	Argentina
Fatrix	Chile
Maximitom	Argentina
Maximiton	Ecuador
Minazol	Colombia
Mitameta	Italien
Mitem	Schweiz, Tyskland
Mitocin	Brasilien
Mitokebir	Argentina, Ecuador
Mitolem	Colombia, Venezuela
Mitomicina	Argentina, Chile, Ecuador, Italien, Mexiko, Peru, Portugal, Rumänien, Spanien
Mitomycin	Belgien, Danmark, Finland, Förenta Staterna, Grekland, Iran, Irland, Italien, Malaysia, Norge, nya Zeeland, Österrike, Polen, Slovenien, Storbritannien, Sverige, Turkiet, Tyskland, Ungern
Mitomycine	Luxemburg, Nederländerna
Mitotie	Argentina, Chile, Ecuador, Peru
Mitozytrex	Förenta Staterna
Mixandex	Colombia, Mexiko
Mutamycin	Förenta Staterna
Riptam	Colombia
Ronzine	Argentina, Peru
Urocin	Tyskland

Hänvisningar : Mitomycin

	Typ	Publikation
3	tidningen	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	tidningen	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	tidningen	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	tidningen	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	tidningen	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	tidningen	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	tidningen	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	tidningen	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	tidningen	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	tidningen	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	tidningen	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
407	tidningen	Quebberman EJ, Hoffman NE, Ausman RK, Hamid AAR. Stability of mitomycin admixtures. Am J Hosp Pharm 1985 ; 42: 1750-1754.
485	tidningen	Dorr RT, Liddil JD. Stability of mitomycin C in different infusion fluids: compatibility with heparin and glucocorticosteroids. J Oncol Pharm Practice 1995 ; 1: 19-24.
648	tidningen	Das Gupta V. Stability of mitomycin aqueous solution when stored in tuberculin syringes. Int J Pharm Compound 1997 ; 1: 282-283.
835	tidningen	Edwards D, Selkirk AB, Taylor RB. Determination of the stability of mitomycin C by high performance liquid chromatography. Int J Pharm 1979 ; 4: 21-26.
905	tidningen	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1026	tidningen	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1178	tidningen	Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL. Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 1981 ; 38: 1914-1918.
1239	tidningen	Stolk LML, Fruijtier A, Umans. Stability after freezing and thawing of solutions of mitomycin C in plastic minibags for intravesical use. Pharm Weekbl [Sci] 1986 ; 8: 286-288.
1410	tidningen	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	tidningen	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1827	tidningen	Beijnen JH, Van Gijn R, Underberg WJM. Chemical stability of the antitumor mitomycin C in solutions for intravesical instillation. J Parenter Sci Technol 1990 ; 44: 332-335.
2247	tidningen	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3128	Laboratorium	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3575	Laboratorium	Mitomycine (Ametycine®) - Résumé des caractéristiques du produit Prostrakan 2013
3897	tidningen	Briot T, Truffaut C, Le Quay L, Lebreton A, Lagarce F. Stability of Reconstituted and Diluted Mitomycin C Solutions in Polypropylene Syringes and Glass Vials. Pharmaceutical Technology in Hospital Pharmacy 2016 ;1,2:83-89
4154	Laboratorium	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4282	tidningen	Myers A-L, Zhang Y-P, Kawedia J-D, Zhou X,. Sobocinski S-M, Metcalfe M-J, Kramer M-A, Dinney C.P.N, Kamat A-M. Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. Drugs R D 2017
4367	tidningen	Kinast R.M, Akula K.K, DeBarber A.E, Barker G.T, Gardiner S.K, Whitson E, Mansberger S.L. The Degradation of Mitomycin C Under Various Storage Methods. J Glaucoma 2016 ; 25, 6: 477-481.
4471	Laboratorium	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019
4526	tidningen	Nisse, Y.E, Vigneron J, Zenier H, D'Huart E, Demoré B. Stability of mitomycin in polypropylene syringes for use in glaucoma surgery. EJOP 2021 4: 1.
4763	tidningen	Almasi J, Erdnuss F, Thiesen J, Krämer I. Physicochemical stability of urea-containing Mitomycin C preparations in glass vials (1.0 mg/mL) and plastic syringes (2.0, 0.4, 0.2 mg/mL) Pharmaceutical Technology in Hospital Pharmacy 2023 ;8,1

Mentions Légales